



(51) International Patent Classification:

C07D 231/14 (2006.01) A61K 31/415 (2006.01)
C07D 403/12 (2006.01) A61K 51/04 (2006.01)

(21) International Application Number:

PCT/EP2013/003700

(22) International Filing Date:

6 December 2013 (06.12.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12008208.6 7 December 2012 (07.12.2012) EP

(71) Applicant: **3B PHARMACEUTICALS GMBH**
[DE/DE]; Magnusstrasse 11, 12489 Berlin (DE).(72) Inventors: **OSTERKAMP, Frank**; Glashütter Weg 36a, 12355 Berlin (DE). **SMERLING, Christiane**; Kadettenweg 52, 12205 Berlin (DE). **REINEKE, Ulrich**; Danckelmannstr. 53, 14059 Berlin (DE). **HAASE, Christian**; Erich-Weinert-Str. 136, 10409 Berlin (DE). **UNGEWIB, Jan**; Rhodeländerweg 46, 12355 Berlin (DE).(74) Agent: **BOHMANN, Armin**; BOHMANN & LOOSEN, Nymphenburger Strasse 1, 80335 München (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NEUROTENSIN RECEPTOR LIGANDS



(I)



(II)

(57) Abstract: The present invention is related to a compound of formula (I) wherein R¹ is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl; AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid; R² is selected from the group consisting of (C₁-C₆)alkyl, (C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkylmethyl, halogen, nitro and trifluoromethyl; ALK is (C₂-C₅)alkylidene; R³, R⁴ and R⁵ are each and independently selected from the group consisting of hydrogen and (C₁-C₄)alkyl under the proviso that one of R³, R⁴ and R⁵ is of the formula (II) wherein ALK' is (C₂-C₅)alkylidene; R⁶ is selected from the group consisting of hydrogen and (C₁-C₄)alkyl; and R⁷ is selected from the group consisting of H and an Effector moiety; or a pharmacologically acceptable salt, solvate or hydrate thereof.

